Final 3-year results of the Dasatinib Discontinuation Trial in Patients with Chronic Myeloid Leukemia who received dasatinib as a second line treatment

We previously reported an interim analysis of the Dasatinib Discontinuation (DADI) trial. The results showed that 48% of patients with chronic myeloid leukemia in chronic phase (CML-CP) who maintained a deep molecular response (DMR) for at least 1 year could discontinue second- or subsequent-line dasatinib treatment safely at a median follow-up of 20 months. However, the results of longer follow-up would be much more useful from a clinical perspective.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 14, 2018 Category: Hematology Authors: Masaya Okada, Jun Imagawa, Hideo Tanaka, Hirohisa Nakamae, Masayuki Hino, Kazunori Murai, Yoji Ishida, Takashi Kumagai, Seiichi Sato, Kazuteru Ohashi, Hisashi Sakamaki, Hisashi Wakita, Nobuhiko Uoshima, Yasunori Nakagawa, Yosuke Minami, Masahiro Ogasawara Tags: Original Study Source Type: research